Presenters
Former Scientific Director of CARIM
Thomas Unger, MD
Course Details
The clinical presentation of hypertension varies widely across populations with different ages, comorbidities and risk profiles. In this video, Professor Thomas Unger discusses the management of hypertension across the full patient spectrum and the role of inhibition of the renin-angiotensin system in improving multiple patient outcomes.
Estimated time of Completion: 40 mins and 58 secs.
CPD Points: 1
Program Number: PROG-2025-97368
Hypertension Management Across the Full Patient Spectrum Course Outline
- Cardiovascular Disease is a continuum: Hypertension stands at
the very beginning - What is Hypertension? ISH vs ACC? AHA Guidelines
- 2020 ISH Global Hypertension Practice Guidelines (Unger T, et al. Hypertension 2020;75:1334-57)
- Hypertension: Cardiovascular-Renal Complications
- Cardiovascular Mortality Risk Doubles with Each 20/10 mmHg Increment in Systolic/Diastolic BP*
- Mortality due to the leading global risk factors
- Exacerbators & Inducers of Hypertension
- Initial evaluation of newly diagnosed hypertension
- Hypertension-mediated Organ Damage (HMOD)
- Cardiovascular Risk Factors
- Which BP target for optimal CV risk benefit?
- Treating hypertension reduces CV risk
- 2020 Philippine Hypertension CPG
- Development of Antihypertensives
- CENTRAL ILLUSTRATION Efficacy and Safety of ACE Inhibitors and ARBs
From Head-to-Head Studies and Compared With Placebo Trials - Unique “delta lock” structure of Telmisartan
- Receptor binding affinity relative to half-life
- Telmisartan: PHARMACOLOGY
- BP Morning Rise: Telmisartan compared with Valsartan: (24-h SBP
reduction after a missed dose: pooled analysis of two independent studies)
- Telmisartan vs Losartan on Trough Ambulatory BP (18-24 Hours Post-Dosing)
- Blood Pressure Response in Mild to Moderate Hypertension
- Telmisartan is superior to losartan in reducing diastolic BP
- Telmisartan is superior to losartan in achieving DBP response* in patients with mild-to-moderate hypertension
- Cardiovascular Disease is a continuum
- HOPE study – primary endpoints
- Telmisartan (80 mg) reduces CV events similar to Ramipril (10 mg) in CV high-risk patients
- ONTARGET: telmisartan versus ramipril on proteinuria
- ONTARGET/TRANSCEND: Percent Permanent Discontinuations due to Side Effects
- New Indication for Telmisartan 80 mg
- For high CV Risk patients, Telmisartan is the only ARB that confers additional CV risk reduction
- Telmisartan vs Ramipril
- Blood Pressure has multiple regulators
- Multiple Antihypertensive Agents are Needed to Reach BP Goal
- Efficacy of Telmisartan + Amlodipine combination
- Rationale for ARB / CCB
- THE PROTECTION PROGRAMME
- Telmisartan compared with losartan reduction in proteinuria (AMADEO)
- AMADEO Overall and cardiovascular composites endpoints
PC-PH-106251 | January 2025